The poster, designed by Dustin Youngman of Wichita, is described as embodying “the rugged Great Plains spirit.” ...

About Idiopathic Multicentric Castleman Disease (iMCD) ...

Recordati Rare Diseases Inc. today announced the presentation of real-world data that build upon the safety data of sutimlimab, an FDA-approved therapy for hemolysis in adults with cold agglutinin ...

The world is a dangerous place, and it might be scarier than we think. Many people even worry about the fate of our ...

New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPCORE DLBCL-3 trial ...

Travel back to the '70s with the beers people reached for most, including Michelob, Miller High Life, Olympia, Stroh's, Coors ...

KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects ...

For the fitness buff in your life, Rebound offers a lighter, cleaner alternative to the usual chalky protein shake. Vancouver-made, these fruity protein powders deliver 20g of protein per serving, ...

Results from CADENCE, the first and largest multinational prospective registry for patients with CAD/CAS, describe safety events observed in patients ...

Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term AYVAKIT® (avapritinib) use across the spectrum of systemic mastocytosis ...

President Donald Trump is hosting a Cabinet meeting, the day after the administration insists that a secondary strike on an ...